New blood thinner could reduce clot risks in heart surgery recovery
NCT ID NCT06276010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a drug called nafamostat mesilate to the standard blood thinner heparin in 80 adults who need a heart-lung machine (ECMO) after heart surgery. The goal is to see which drug better prevents dangerous blood clots while causing fewer bleeding problems. Participants will be monitored for clot events and bleeding complications during their ECMO treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRACORPOREAL MEMBRANE OXYGENATION COMPLICATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital
RECRUITINGBeijing, Beijing Municipality, 100029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••